Follow-Up for Reactive Squamous and Endocervical Glandular Cells in a 43-Year-Old Woman
A 43-year-old woman with reactive squamous and endocervical glandular cells on Pap smear requires routine screening follow-up only—no immediate colposcopy or additional testing is needed.
Understanding Reactive Cellular Changes
Reactive cellular changes represent benign alterations in cervical cells responding to inflammation, infection, trauma, or hormonal influences. These are not classified as atypical glandular cells (AGC) or any form of dysplasia. The term "reactive" specifically indicates that the cellular changes are benign and do not suggest pre-malignant or malignant processes.
The provided guidelines 1 focus exclusively on management of abnormal Pap test results including ASC-US, ASC-H, LSIL, HSIL, and AGC. Reactive changes do not fall into any of these abnormal categories and therefore do not trigger the ASCCP management algorithms.
Recommended Management Algorithm
For this 43-year-old patient:
- Return to routine age-appropriate screening intervals
- Since she is between ages 30-65, appropriate options include:
No additional interventions are warranted:
- No colposcopy
- No repeat Pap in 6-12 months
- No HPV testing (unless part of routine co-testing strategy)
- No endocervical or endometrial sampling
Key Clinical Distinctions
It is critical to distinguish reactive changes from true atypical glandular cells (AGC). The research evidence 4, 5, 6 demonstrates that AGC carries significant risk—with 20-32% of AGC cases harboring pre-malignant or malignant lesions including cervical adenocarcinoma in situ, invasive cervical cancer, or endometrial cancer. However, reactive changes carry no such risk.
If the cytology report had instead indicated "atypical glandular cells," the management would be entirely different, requiring:
- Colposcopy with endocervical sampling
- Endometrial assessment (particularly in women ≥35 years or with risk factors) 4, 5, 6
Common Pitfalls to Avoid
Do not over-manage benign findings:
- Reactive changes are common and clinically insignificant
- Unnecessary colposcopy increases patient anxiety, healthcare costs, and potential for harm without benefit
- The absence of this scenario in ASCCP guidelines 1 reflects that reactive changes require no special management
Ensure accurate cytology interpretation:
- Confirm the report states "reactive" and not "atypical glandular cells" or "AGC"
- If any uncertainty exists about the cytology interpretation, consider discussing with the pathologist before proceeding
Address underlying causes if symptomatic:
- If the patient has symptoms (abnormal bleeding, discharge, pain), investigate and treat the underlying inflammatory or infectious process
- Common causes include cervicitis, vaginitis, IUD presence, recent procedures, or hormonal changes
- Treatment of the underlying condition does not change screening recommendations
Age-Specific Considerations
At age 43, this patient remains in the standard screening age range (21-65 years) 2, 3. She should continue routine screening until age 65, at which point screening can be discontinued if she has adequate negative prior screening history (3 consecutive negative cytology tests or 2 consecutive negative co-tests within 10 years, with the most recent within 5 years) 3.